Key clinical point: A single educational mailing sent to patients with atrial fibrillation who were candidates for oral anticoagulation, but had not yet started a regimen, failed to get them started on an antithrombotic regimen.
Major finding: By 1 year following the intervention, 10% of patients in both the intervention and a control arm of the randomized trial had begun treatment.
Study details: IMPACT-AF was a randomized trial of more than 47,000 atrial fibrillation patients who had not adopted an antithrombotic regimen.
Disclosures: IMPACT-AFib received no commercial funding, and Dr. Pokorney and Dr. Shivkumar had no disclosures. Dr. Leclercq has received honoraria from Abbott, Biotronik, Boston Scientific, Livanova, and Medtronic.
FROM ESC CONGRESS 2020